Moreover, in low-risk MDS patients responding to ESAs therapies, namely erythropoietin (EPO) [86], EPO was associated with several inositide signaling pathways, such as PI3K/Akt/PLCγ1, resulting in apoptosis and a low proliferation rate of MDS cells. Here, PLCG1 is linked to myelodysplastic syndrome.